Natera Highlights Signatera’s Potential in Bladder Cancer at ESMO 2026
AUSTIN, Texas, United States — October 27, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
AUSTIN, Texas, United States — October 27, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision...
LAWRENCEVILLE, N.J. — September 22, 2026 IMUNON announced that the Independent Data Monitoring Committee (IDMC) overseeing its Phase 2...
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
Palo Alto, California — September 4, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has...
Silver Spring, Maryland, USA, September 4, 2026 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
Cambridge, UK — September 4, 2026 AstraZeneca announced that ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor has received...
AUSTIN, Texas, September 1, 2026 Natera announced publication of new clinical data in Blood Neoplasia supporting the prognostic and...
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
Tuebingen, Germany — August 26, 2026 HepaRegeniX GmbH announced that the U.S. FDA has granted Orphan Drug Designation (ODD)...
Lawrenceville, New Jersey – August 26, 2026 IMUNON announced plans to host its 2026 R&D Day on September 23...
